Spred1 Antibody
| Code | Size | Price |
|---|
| PSI-4843-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4843-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
Spred1 Antibody: NFLS, hSpred1, spred-1, Sprouty-related, EVH1 domain-containing protein 1, Spred-1
Application Note:
Spred1 antibody can be used for detection of Spred1 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
Spred1 Antibody: The Ras-MAP kinase pathway is essential for the differentiation of neuronal cells and myocytes; it is inhibited by Spred1, a member of the Sprouty family of proteins. Spred1 acts by suppressing the phosphorylation and activation of Raf. The Spred proteins have also been implicated in the negative feedback regulation of FGF signaling in embryogenesis and angiogenesis. Further studies have shown that expression levels of Spred1 and Spred2 proteins are inversely correlated with the incidence of tumor invasion and metastasis in human hepatocellular carcinoma (HHC), suggesting that these proteins could be useful as prognostic factors and therapeutic targets in HCC. Defects in this gene are a cause of neurofibromatosis type 1-like syndrome (NFLS).
Background References:
- Wakioka T, Sasaki A, Kato R, et al. Spred is a Sprouty-related suppressor of Ras signalling. Nature 2001; 412:647-51.
- Minowada G, Jarvis LA, Chi CL, et al. Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development 1999; 126:4465-75.
- Lee SH, Schloss DJ, Jarvis L, et al. Inhibition of angiogenesis by a mouse sprouty protein. J. Biol. Chem. 2001; 276:4128-33.
- Yoshida T, Hisamoto T, Akiba J, et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 2006; 25:6056-66.
Buffer:
Spred1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Spred1 antibody was raised against a 14 amino acid synthetic peptide near the center of the human Spred1.
The immunogen is located within amino acids 250 - 300 of Spred1.
The immunogen is located within amino acids 250 - 300 of Spred1.
NCBI Gene ID #:
161742
NCBI Official Name:
sprouty-related, EVH1 domain containing 1
NCBI Official Symbol:
SPRED1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 49 kDa
Observed: 498 kDa
Observed: 498 kDa
Protein Accession #:
NP_689807
Protein GI Number:
22749221
Purification:
Spred1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
SPECIFICITY:
This Spred1 antibody is predicted to have no cross-reactivity to Spred2 or Spred3.
Swissprot #:
Q7Z699
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | Spred1 Peptide | PSI-4843P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|